# A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

> **NCT05676203** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jena University Hospital** · enrollment: 250 (actual)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Standard ADT (androgen deprivation therapy)
- **DRUG:** Standard Darolutamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05676203
- **Lead sponsor:** Jena University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-16
- **Primary completion:** 2025-07
- **Final completion:** 2027-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676203, "A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05676203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*